Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. To better understand the genetic etiology of osteosarcoma, we performed a multistage genome-wide association study consisting of 941 individuals with osteosarcoma (cases) and 3,291 cancer-free adult controls of European ancestry. Two loci achieved genome-wide significance: a locus in the GRM4 gene at 6p21.3 (encoding glutamate receptor metabotropic 4; rs1906953; P = 8.1 × 10 −9 ) and a locus in the gene desert at 2p25.2 (rs7591996 and rs10208273; P = 1.0 × 10 −8 and 2.9 × 10 −7 , respectively). These two loci warrant further exploration to uncover the biological mechanisms underlying susceptibility to osteosarcoma.
l e t t e r s
Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. To better understand the genetic etiology of osteosarcoma, we performed a multistage genome-wide association study consisting of 941 individuals with osteosarcoma (cases) and 3,291 cancer-free adult controls of European ancestry. Two loci achieved genome-wide significance: a locus in the GRM4 gene at 6p21.3 (encoding glutamate receptor metabotropic 4; rs1906953; P = 8.1 × 10 −9 ) and a locus in the gene desert at 2p25.2 (rs7591996 and rs10208273; P = 1.0 × 10 −8 and 2.9 × 10 −7 , respectively). These two loci warrant further exploration to uncover the biological mechanisms underlying susceptibility to osteosarcoma.
Osteosarcoma is the most common primary malignant bone tumor in children and young adults, affecting approximately four persons per million each year in the United States 1 . Peak incidence correlates with the pubertal growth spurt, occurring earlier in females than in males. It is more common at sites of rapid bone growth. Tall stature and high birth weight are proven risk factors 2 , and osteosarcoma is a syndromeassociated malignancy in the Li-Fraumeni, Rothmund-Thomson and hereditary retinoblastoma cancer susceptibility syndromes. Several small case-control studies have reported preliminary associations of common genetic variants with osteosarcoma risk in biologically plausible pathways [3] [4] [5] [6] [7] [8] [9] [10] [11] (for example, growth and DNA repair), but statistical power has been limited by small sample sizes 12 .
We developed an international, multi-institutional collaborative effort to conduct a genome-wide association study (GWAS) of osteosarcoma (Supplementary Table 1 ). We extracted germline genomic DNA from either blood or buccal cells obtained from osteosarcoma case series using standard methods. Participating subjects provided informed consent under the auspices of local institutional review boards (IRBs). We selected control subjects from previously scanned cancer-free adults over the age of 55 years drawn from large case-control and cohort studies, using an approach that was successfully applied for Ewing sarcoma 13 and pediatric acute lymphoblastic leukemia (ALL) 14 .
We conducted genotyping of all cases using the Illumina OmniExpress SNP microarray, with samples over time being divided into two stages, which we call stage 1a and 1b, owing to the staggered Genome-wide association study identifies two susceptibility loci for osteosarcoma l e t t e r s receipt of the samples in this multi-institutional study design (Online Methods and Supplementary Fig. 1) . In stage 1a, we genotyped 910 available osteosarcoma cases from 5 studies. On the basis of quality control filtering (including for locus and sample missing rates, sample heterozygosity, departure from Hardy-Weinberg equilibrium and sex discrepancies) and assessment of underlying population substructure (STRUCTURE and principal-components analyses (PCA)), we included 596 cases of European ancestry in the primary GWAS analysis (Supplementary Figs. 2 and 3) ; 97 African-American and 99 Hispanic cases were identified and excluded from the present analysis. In stage 1b, we genotyped a later collection of samples consisting of 218 osteosarcoma cases using the OmniExpress SNP microarray (Supplementary Table 1 ). We applied the same quality control filtering and population substructure analyses as for stage 1a, yielding an additional 98 cases of European ancestry for the final analysis. The choice of SNPs for follow-up was based on association results for the first set (stage 1a), but, for the final analysis, we present the results of the full set of 694 cases (namely, combined stages 1a and 1b).
Overall, 698,968 SNPs passed quality control metrics for the full set of 694 cases for final analysis. The numbers of SNPs overlapping those genotyped in pooled controls were 510,856, 510,856, 310,384 and 304,092 for the US, Spanish, Italian and UK components, respectively, and we used these SNPs in the association analyses (Online Methods).
We combined data from already scanned controls drawn from two large cohort studies (the Prostate, Lung, Colon and Ovarian Cancer Prevention Trial (PLCO) 15 and the American Cancer Society Cancer Prevention Study II (CPSII) 16 19 scanned on the Illumina HumanHap550 SNP microarray). We selected 2,703 controls on the basis of comparable quality control metrics for comparison with the scanned cases. We conducted a systematic assessment of the underlying population substructure to remove highly admixed individuals (with non-European admixture of >20%) from a model to investigate cases of European ancestry ( Supplementary Figs. 2 and 3) .
We performed association analyses using a 1-degree-of-freedom trend test adjusted by sex and eigenvectors. We designed optimized TaqMan assays based on SNP associations observed in the first set of cases in the scan (stage 1a; Supplementary Table 2) .
The locus at 6p21.3, marked by rs1906953, was associated with susceptibility to osteosarcoma (P = 8.0 × 10 −9 ; odds ratio (OR) = 1.57, 95% confidence interval (CI) = 1.35-1.83) ( Table 1 ). The rs1906953 SNP is located in intron 7 (g.34036446C >T) of the GRM4 gene encoding glutamate receptor metabotropic 4 (Fig. 1a) . The most significantly associated SNP in this region resides within GRM4 in a distinct haplotype block from the human leukocyte antigen (HLA) class II region, which is more than 1 Mb telomeric at 6p21.3. It is also notable that between the HLA class II region and the region associated with osteosarcoma risk is a distinct region containing BAK1, which in published GWAS analyses has been conclusively associated with platelet counts [20] [21] [22] , chronic lymphocytic leukemia 23 and testicular germ cell tumors 24 .
The C reference allele of rs1906953 in GRM4 was highly conserved, and its frequency was higher in African populations; the global minor allele frequency (MAF) was 0.29 in 1000 Genomes Project data (Phase 1 genotype data from 1,094 individuals) 25 , with greater frequency of the T allele in individuals of Asian or African ancestry (MAF = 0.46 and 0.56, respectively). Although there were four surrogates for this SNP in individuals of European ancestry (r 2 > 0.6 within ± 500 kb) in 1000 Genomes Project data, the index SNP rs1906953 mapped to a DNase I hypersensitivity region in the Encyclopedia of DNA Elements (ENCODE) 26 data set, raising the possibility that the variant contributing to osteosarcoma risk is within a region of open chromatin (Supplementary Table 3 ) and could contain active regulatory elements. One intronic surrogate SNP (rs73410895) was predicted to alter known regulatory motifs, including HMG-IY, Pou3f2 and Pou1f1 (Supplementary Table 3) .
GRM4 is a plausible candidate gene in osteosarcoma that has been implicated in intracellular signaling and inhibition of the cyclic AMP (cAMP) signaling cascade. In mice, a cAMP-dependent protein kinase (Prkar1a) is an osteosarcoma tumor suppressor gene 27, 28 , suggesting that the cAMP pathway is important in osteosarcoma. Although glutamate signaling is best characterized in the central nervous system (CNS), where it is known to be involved in the excitability of gonadotropin-releasing hormone neurons, it also occurs in bone 29 . The GRM4 receptor is expressed in bone osteoblast (bone-building) and npg l e t t e r s osteoclast (bone-resorbing) cells, suggesting that glutamate signaling is involved in cell differentiation and regulation during bone formation and resorption 30 . GRM4 is expressed in human osteosarcoma cells 31 and is associated with poor prognosis in colorectal cancer 32 , pediatric CNS tumors 33 , rhabdomyosarcoma and multiple myeloma 34 , as well as with cancer cell proliferation in vitro 35 . We observed a second association signal in an intergenic region at 2p25.2 (Fig. 1b) , with the rs7591996 SNP achieving genome-wide significance (OR = 1.39, 95% CI = 1.23-1.54; P = 1.0 × 10 −8 ). A second SNP, rs10208273, was moderately correlated with the first signal (r 2 = 0.32 in HapMap 3 release 2) and approached genome-wide significance (OR = 1.35, 95% CI = 1.21-1.52; P = 2.9 × 10 −7 ) (Fig. 1b and Table 1 ). The risk allele frequency for rs7591996 was 0.50 in osteosarcoma cases of European ancestry and 0.45 in controls. rs7591996 had a global MAF of 0.38 in 1000 Genomes Project data; the risk allele was the minor allele in CEU individuals (Utah residents of Northern and Western European ancestry) and the major allele in individuals of Asian or African ancestry (MAF = 0.35 and 0.14, respectively). Both rs7591996 and rs10208273 occur in a region of relatively low linkage disequilibrium (LD) (Fig. 1b) . Data from the 1000 Genomes Project for European populations documented at least 27 surrogate SNPs (r 2 > 0.6 within ± 500 kb). According to ENCODE 26 data, the two index SNPs did not localize to a region of active regulatory elements or transcription factor binding sites. However, several of the surrogate SNPs altered known regulatory motifs and transcription factor binding sites (Supplementary Table 3 ) and may affect gene expression. These findings suggest that further sequencing and fine mapping will be required to determine which variants will be optimal for the functional studies needed to explain disease association.
Finally, we report a third locus that was promising but did not yet achieve genome-wide significance, rs17206779 (OR = 0.75, 95% CI = 0.68-0.84; P = 5.1 × 10 −7 ), located in the ADAMTS6 gene encoding ADAM metallopeptidase with thrombospondin type 1 motif 6 (g.64447777C > T) at 5q12.3. It is notable that variations in genes encoding members of the ADAMTS protein family have been associated with height 36 , a known risk factor for osteosarcoma 2 . Further data are required to confirm the association of this locus and to then fine map the region before conducting functional studies.
To further explore the two significantly associated regions reported in this study, we imputed SNPs on the basis of 1000 Genomes Project data (March 2012 release) together with the DCEG Imputation Reference Set version 1 (ref. 37) using the IMPUTE2 program 38 across a 1-Mb region centered on each index SNP (Online Methods). A subsequent association analysis did not identify new signals that were substantially stronger than those of the genotyped SNPs for either the 2p25.2 or 5q12.3 region (Supplementary Fig. 4) . Although there seemed to be stronger signals in the imputed data for the HLA class II region (Supplementary Fig. 4a ), there is a strong recombination hotspot separating it from the region marked by the rs1906953 index SNP. It will be critical to pursue more detailed mapping and genotyping of the HLA class II region to determine whether there is an independent signal in addition to the one that resides in GRM4.
An assessment of the loci previously reported in candidate gene association studies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] did not show overlap with any of the reported npg l e t t e r s loci approaching genome-wide significance (Supplementary Table 4 ). It is notable that the SNPs in the 8q24.3 region and the multicancer-associated 8q24.21 region seemed to be promising candidates 10 ; the strongest signal among a set of highly correlated SNPs at 8q24.21, rs11777807, had association P = 4.6 × 10 −5 , and rs369051 at 8q24.3 had association P = 1.16 × 10 −4 . Further studies are needed to determine whether these are stable associations or were perhaps due to chance. Through a multistage GWAS of osteosarcoma, we have identified two susceptibility regions at 2p25.2 and 6p21.3, with the latter harboring a plausible candidate gene, GRM4. It is noteworthy that the loci we have identified demonstrate estimated ORs greater than 1.5, which are higher than those observed for most variants associated with cancer risk in adults. Our findings are consistent with the high risk estimates reported for Ewing sarcoma 13 and ALL 14 , other rare pediatric tumors. Further investigation of these associated loci is warranted to uncover the biological mechanisms underlying susceptibility to osteosarcoma.
URLs. Cancer Genetic Markers of Susceptibility (CGEMS) portal, http://cgems.cancer.gov/; CGF, http://cgf.nci.nih.gov/; GLU, http:// code.google.com/p/glu-genetics/; EIGENSTRAT, http://genepath.med.harvard.edu/~reich/EIGENSTRAT.htm; STRUCTURE, http://pritch.bsd.uchicago.edu/structure.html; PLINK, http://pngu. mgh.harvard.edu/~purcell/plink/; SequenceLDhot, http://www. maths.lancs.ac.uk/~fearnhea/Hotspot/; snp.plotter, http://cbdb. nimh.nih.gov/~kristin/snp.plotter.html; PHASE v2.1, http://www.stat. washington.edu/stephens/phase/download.html; IMPUTE2, http:// mathgen.stats.ox.ac.uk/impute/impute_v2.html; SNPTEST, https:// mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html.
METhOds
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.

ONLINE METhOds
Genome-wide SNP genotyping. Genome-wide SNP genotyping of osteosarcoma cases was conducted using the Illumina OmniExpress BeadChip at the NCI Cancer Genomics Research Laboratory (CGR) in the Division of Cancer Epidemiology and Genetics (DCEG) at the National Cancer Institute. Genotype analysis occurred in two stages because of the sequential receipt of samples. Stage 1a consisted of 910 unique cases from the Children's Oncology Group (COG), Toronto Study, PamplonaCUN, Rizzoli (Italy), Ankara (Turkey) and UCL. Adult, cancer-free controls were drawn from previously scanned studies in the United States, namely, PLCO and CPS-II of the American Cancer Society, both scanned on the Illumina Omni 2.5M SNP microarray. European controls were drawn from EAGLE (Italy) scanned on the HumanHap550 array, WTCCC (UK) scanned on the HumanHap550 array and the NCI Spanish Bladder Cancer Study scanned on the HumanHap 1M SNP array. Stage 1b consisted of 218 unique cases scanned on the OmniExpress BeadChip drawn from the UCL, Rizzoli and PamplonaCUN studies plus 2 additional studies from the Sir Peter MacCallum Department of Oncology (Australia) and Brazil. Cancer-free adult controls were drawn from PLCO and NHS, scanned on the Illumina Omni 2.5M and OmniExpress arrays, respectively.
Each participating study obtained informed consent from study participants and approval of the study from its IRB; studies also obtained IRB certification permitting data sharing in accordance with the US National Institutes of Health (NIH) Policy for Sharing of Data Obtained in NIH-Supported or -Conducted Genome-Wide Association Studies (GWAS). The CGEMS data portal provides access to individual-level data from the National Cancer Institute scan only to investigators from certified scientific institutions after approval of their submitted Data Access Request.
Quality control assessment.
We conducted systematic quality control that included steps specific for the scanning of different arrays at distinct times. For SNP assays, exclusions included SNPs with less than a 90% completion rate and those with extreme deviation from fitness for Hardy-Weinberg proportion (P < 1 × 10 −7 ). There were 29 duplicated cases in stages 1a and 1b; concordance rates were 99.96%.
Analysis of stage 1a. In the quality control analysis of stage 1a, samples were excluded on the basis of (i) completion rates lower than 94% (n = 28 samples); (ii) abnormal heterozygosity values of less than 20% or greater than 31% (n = 8); (iii) expected duplicates (n = 23 pairs); (iv) abnormal X-chromosome heterozygosity (n = 1); and (v) phenotype exclusion (due to ineligibility or incomplete information) (n = 57). Genotypes for all subject pairs were also examined for close relationships (presence of first-and second-degree relatives) using the GLU (Genotyping Library and Utilities version 1.0) qc.ibds module with an IBD0 threshold of 0.70; no first-degree relatives were identified in the cases scanned.
Using a set of 12,000 unlinked SNPs (pairwise r 2 < 0.004) common to the GWAS chips used herein 33 , we excluded 264 subjects with less than 80% European ancestry, as determined using STRUCTURE analysis 34 and PCA 35 ; a majority of these represent 97 cases of African-American ancestry and 99 cases of Hispanic ancestry. The final association analysis for stage 1a included 596 cases and 2,703 controls of European ancestry. After quality control filtering, data from 698,968 SNPs were available. The numbers of SNPs overlapping those of pooled controls were 510,856, 510,856, 310,384 and 304,092 for the US, Spanish, Italian and UK components, respectively, and these SNPs were used in the downstream association analyses.
Analysis of stage 1b. Similar quality control metrics were applied to the second set of additional scanned cases, stage 1b. For the current analysis, we included 98 additional cases in the association analysis of individuals of European ancestry.
Quality control metrics for previously scanned cancer-free adult controls. Pooled PLCO controls were scanned on the Illumina Omni 2.5M array. We excluded (i) samples with missing rates of >6%; (ii) SNPs with missing rates of >10%; (iii) samples with mean heterozygosity of >21% or <16%; (iv) one sample from each cryptic related pair; and (v) non-CEU admixed individuals, identified by STRUCTURE analysis. Pooled SPBC controls were scanned on the Illumina 1M SNP array; details of genotype quality control were previously described 17 . Pooled EAGLE controls were scanned on the Illumina 550K SNP array; details of genotype quality control were previously published 18 . Pooled WTCCC controls were previously described 39 .
Replication and TaqMan genotyping. We conducted a follow-up analysis of the 30 SNPs selected for replication (based on stage 1a data) using TaqMan genotyping assays (ABI) that were optimized in the CGR pipeline. We analyzed a total of 247 cases and 550 controls; the studies included 99 histologically confirmed osteosarcoma cases and 65 hospital-based cancer-free pediatric controls from the National Osteosarcoma Etiology Study Group plus 148 cases drawn from the studies used in the scan in which there was insufficient DNA for array analysis. Cancer-free controls were also selected from the PLCO and NHS studies (previously analyzed on the Illumina Omni 2.5M and OmniExpress arrays, respectively).
Statistical analysis.
Associations between SNPs and risk of osteosarcoma were estimated using unconditional logistic regression by OR and 95% CI, using multivariate unconditional logistic regression assuming a trend genetic model (with the effect of the variant included in a log-additive model with 1 degree of freedom). When included in the null model, PCA identified four significant (P < 0.05) eigenvectors. The main effect model was adjusted by sex, country and four eigenvectors, identified on the basis of significance (P < 0.05) observed in the null model. For the replication study, the analysis was adjusted only for sex.
For stage 1 (1a and 1b), in addition to joint analysis, a fixed-effect metaanalysis was performed to combine results for cases from each country (component) to facilitate the filtering out of artifacts by checking for heterogeneity across countries. Similar meta-analysis was also performed to combine scan (discovery) association results with TaqMan (replication) association results for the 30 SNPs that were analyzed in both stages.
The estimated inflation factor λ and the adjusted λ 1,000 inflation factor for the test statistic from combined stage 1a and 1b data were 1.036 and 1.033, respectively. Recombination hotspots were identified in the vicinity of osteosarcoma-associated loci at 6p21.31 and 2p25.2 using SequenceLDhot 40 , a program that uses an approximate marginal likelihood method 41 and calculates likelihood ratio statistics at a set of possible hotspots. We tested 5 unique sets of 100 control samples. We used the PHASE v2.1 program to calculate background recombination rates 42, 43 . The LD heatmap was visualized in r 2 using the snp.plotter R program 44 .
Imputation. To further interrogate the loci associated with osteosarcoma, we imputed additional SNPs within 1 Mb of either side of each implicated SNP using IMPUTE2 software and reference data from both the 1000 Genomes Project 13 and the DCEG Imputation Reference Set version 1 (ref. 37) . We used SNPTEST to analyze the posterior SNP dosages from IMPUTE2, adjusting for sex, country and four eigenvectors, as described 45 .
Data analysis. Data analysis and management were performed with GLU, PLINK, EIGENSTRAT, IMPUTE2 and SNPTEST.
